Wall Street Zen Upgrades DaVita (NYSE:DVA) to Buy

DaVita (NYSE:DVA) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

Several other equities research analysts have also commented on the stock. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Truist Financial set a $158.00 target price on DaVita in a research report on Thursday, February 5th. UBS Group boosted their price target on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Barclays raised their price target on DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. Finally, Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $155.80.

DaVita Price Performance

NYSE:DVA opened at $150.89 on Friday. The firm has a market capitalization of $10.08 billion, a P/E ratio of 15.23, a P/E/G ratio of 0.51 and a beta of 0.99. The business has a 50 day simple moving average of $120.72 and a 200 day simple moving average of $125.28. DaVita has a 12-month low of $101.00 and a 12-month high of $157.12.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same quarter in the previous year, the company posted $2.24 earnings per share. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Research analysts anticipate that DaVita will post 10.76 EPS for the current fiscal year.

Hedge Funds Weigh In On DaVita

Hedge funds have recently modified their holdings of the stock. Hantz Financial Services Inc. boosted its position in shares of DaVita by 48.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. Gen Wealth Partners Inc raised its holdings in shares of DaVita by 10.0% during the fourth quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after acquiring an additional 80 shares during the period. MAI Capital Management lifted its position in shares of DaVita by 23.4% in the 2nd quarter. MAI Capital Management now owns 438 shares of the company’s stock valued at $62,000 after acquiring an additional 83 shares in the last quarter. NewEdge Advisors LLC boosted its stake in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares during the period. Finally, Teacher Retirement System of Texas grew its position in DaVita by 1.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock worth $954,000 after purchasing an additional 94 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.